Amlitelimab
Based on 1 publication(s) in Google Scholar
Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99%
- CAS. Nr.: 2378692-15-8
- Molecular Weight:145.94 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Amlitelimab
More
Biologische Aktivität
Human IgG4 kappa
Human
TNFSF4/OX40L/CD252
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X10^6 Jurkat cells labeling Amlitelimab (HY-P99434, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized Human OX40 Ligand/TNFSF4 Protein (ECD, mFc Tag) can bind Amlitelimab. The EC50 for this effect is 3.87 ng/mL. -
Loaded Amlitelimab on AHC2 biosensor, can bind OX40 Ligand/TNFSF4 (HEK293, His, HY-P70622) with an affinity constant of <1.000E-11 M as determined in BLI assay.
Chemical Information
-
CAS. Nr. 2378692-15-8
-
Appearance Liquid
-
Molecular Weight 145.94 kDa
-
Color Colorless to light yellow
-
SMILES
[Amlitelimab]
-
Synonyms
KY1005; SAR445229
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Reinheit & Dokumentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[2]. Saghari M, et al. OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005. Clin Pharmacol Ther. 2022 May;111(5):1121-1132. [Content Brief]
[3]. Tkachev V, et al. Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med. 2017 Sep 20;9(408):eaan3085. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)